Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
Mazen Noureddin, MD, MHSc, of Houston Methodist Hospital discusses phase 2 data for GSK's once-monthly FGF21 analog efimosfermin presented at The Liver Meeting 2026 and what the findings mean for ongoing phase 3 trials in MASH and compensated cirrhosis.
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
In the first part of a two-part interview, Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center explains which early patient responses led to the dostarlimab study behind Jemperli's rectal cancer approval, and why mismatch repair-deficient tumors are so visible to the immune system.
Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.
DISCO Pharmaceuticals will receive $40 million upfront, with up to $2.5 billion in potential milestones, to discover bispecific therapeutics for AbbVie that recognize pairs of tumor surface proteins, an approach intended to limit toxicity in healthy tissue.
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.